Sujanu (ipragliflozin/sitagliptin) / Astellas, Merck (MSD) - LARVOL DELTA

Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer. (PubMed, Diabetol Int) - "Her HbA1c was controlled at 6.4%-7.5% using metformin, ipragliflozin, and sitagliptin. Two-and-a-half years later, she was diagnosed with endometrial cancer with pelvic lymph node metastasis and underwent surgery followed by chemotherapy with carboplatin and paclitaxel, then carboplatin and docetaxel...On DAY 36, her plasma glucose (PG) concentration was high; therefore, insulin degludec was administered once daily and self-monitoring of blood glucose commenced...Human leukocyte antigen analysis revealed two susceptibility haplotypes (DRB1*04:05-DQB1*04:01-DPB1*02:01 and DRB1*04:05-DQB1*04:01-DPB1*05:01) for type 1 diabetes (T1D). This case is notable in that pembrolizumab-related T1D progressed more slowly than previously reported, and lenvatinib may have contributed to this delay."

Journal • Diabetes • Endometrial Cancer • Metabolic Disorders • Oncology • Solid Tumor • Type 1 Diabetes Mellitus • HLA-DRB1

Difference in Glycemic Control between Ipragliflozin (Ipra) and Sitagliptin (Sita) according to Fatty Liver Index (FLI)—Post Hoc Analysis of the Results of the Niigata Ipragliflozin and Sitagliptin with Metformin (NISM) Study (ADA 2024) - "There was no difference in changes in the FLI in the low FLI group (-8.1 vs. -2.7, p = 0.051), but in the high FLI group, FLI improved significantly (-13.5 vs. -0.8, p <0.001) with Ipra compared with Sita. The FLI is effective in drug selection for type 2 diabetes."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. (PubMed, Cardiovasc Diabetol) - "While ipragliflozin and sitagliptin showed similar effects on glycemic parameters, the effects on serum lipid and apolipoprotein profiles were different. Ipragliflozin may have an anti-atherogenic effect through modulation of HDL-C and apo E compared to sitagliptin through TG and apo B48, CII, and CIII in patients with type 2 diabetes."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • APOA1 • APOE • LEP

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study. (PubMed, Clin Drug Investig) - "Switching from sitagliptin to ipragliflozin did not alter HbA1c in obese patients with type 2 diabetes, while improving parameters related to organ homeostasis. These data provide novel information useful for selecting oral anti-diabetic agents for patients with type 2 diabetes with obesity, a risk factor for developing various complications of diabetes."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis. (PubMed, Adv Ther) - "This NMA showed that, to reduce genital infection risk, current evidence favors DPP4 inhibitors over SGLT2 inhibitors. Most SGLT2 inhibitors may not be associated with the risk of urinary tract infections. Considering both infection risks, saxagliptin may be the safest drug. Finally, mechanistic studies are needed to better understand the physiological basis for these effects."

Journal • Retrospective data • Review • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. (PubMed, Diabetes Obes Metab) - "The HbA1c-lowering effect at 24 weeks was greater with sitagliptin than with ipragliflozin, but with no difference in efficacy related to HbA1c and body weight at 52 weeks. However, some ASCVD risk factors improved with ipragliflozin."

Clinical • Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

[VIRTUAL] Randomized Controlled Trial of Ipragliflozin or Sitagliptin Combined with Metformin in Type 2 Diabetes: NISM Study (ADA 2020) - "BMI, C-peptide and HDL-C improved with Ipra vs. Sita (p<0.05). Withdrawal for any adverse event occurred in 8 with Ipra and 4 with Sita (14.8% and 7.0%, p=0.23).Although glycemic control did not differ between Ipra and Sita, some ASCVD risk factors improved with Ipra."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Predictors of the Glucose-Lowering or Weight-Loss Effects of Ipragliflozin and Sitagliptin (ADA 2019) - "ΔHbA1c had a significant negative correlation with HbA1c level at the baseline (ρ = -0.42, p = 0.0016), but no significant correlation with other variables at the baseline.In conclusion, our results suggest that the glucose-lowering effects of Ipra were more prominent in younger patients with increased insulin resistance accompanied by fatty liver, while its weight-loss effects were more prominent in patients with high total ketone concentration at the baseline. Meanwhile, the glucose-lowering effects of Sita may be exhibited regardless of the patient pathology."